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The purpose of the WHO scientific review on trans fatty acids (TFAs) was to examine the evidence generated since the 1993 Joint 
FAO/WHO Expert Consultation on Fats and Oils in Human Nutrition, and to inform member countries on the health 
consequences of TFAs consumption that have emerged since the last report was released. The new information was deemed 
sufficient to recommend the need to significantly reduce or to virtually eliminate industrially produced TFA from the food supply 
in agreement with the implementation of the 2004 WHO Global Strategy on Diet, Physical Activity and Health. This goal has 
been accomplished in some countries and cities, by the virtual elimination of partially hydrogenated vegetable oils in the human 
food supply, replacing them with healthy c/s-unsaturated fatty acids. The document provides the evidence base to promote 
discussion between the international scientific community related to nutrition and health as well as between agriculturalists, 
food producers, relevant health professionals, national and international food regulatory agencies, civil society and the private 
sector to achieve the stated goal.
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Introduction
The WHO Scientific Update considered new evidence on the 
health consequences that have emerged on trans fatty acids 
(TFAs) since the last Joint FAO/WHO Expert Consultation 
on Fats and Oils in Human Nutrition was held in 1993 (FAO, 
1994) and the Joint WHO/FAO Expert Consultation on Diet, 
Nutrition and the Prevention of Chronic Diseases (WHO, 
2003; Nishida et al., 2004). The new data considered by the 
group was deemed sufficient to support recommendations, 
leading to a significant reduction or virtual elimination of 
industrially produced TFA for the implementation of the
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Global Strategy on Diet, Physical Activity and Health (WHO, 
2004). The Scientific Update enabled a number of conclu­
sions to be drawn and to establish recommendations for the 
elimination of industrially produced TFA from the food 
supply. This Scientific Update applied similar criteria to 
those used by the 2002 WHO/FAO Expert Consultation on 
Diet, Nutrition and the Prevention of Chronic Diseases 
(WHO, 2003) and the Joint FAO/WHO Scientific Update on 
carbohydrates in human nutrition (Nishida and Martinez 
Nocito, 2007) to describe the strength of evidence and to 
draw conclusions from the scientific review of the totality of 
the evidence, including both randomized controlled studies 
in humans and observational studies involving long­
term follow-up of cohorts and experimental animal and 
laboratory studies when no other data were available. The 
aim of the present report is to provide a summary of the
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scientific reviews of the evidence prepared by the experts and 
the conclusions of the discussions of this expert group 
prepared in response to the updated evidence presented at 
the meeting in Geneva on 29-30 October 2007. This 
Scientific Update represents the collective view of the 
participating experts, acting in their own personal capacity.
The experts included Antti Aro, Robert Clarke, Rasheed 
Ghafoorunissa, Mary L'Abbé (Rapporteur), Dariush 
Mozaffarian, C Murray Skeaff, Steen Stender, Marcelo Tavella 
and Ricardo Uauy (Chairman), who were selected on the 
basis of their scientific background and geographic repre­
sentation. The Secretariat members included Denis Aitken, 
Timothy Armstrong, Vanessa Candeias, Chizuru Nishida, 
Christophe Roy, Jorgen Schlundt and Jonathan Siekmann 
and Frank Martinez Nocito who served as a temporary 
advisor. FAO, represented by Gina Kennedy, also participated 
in the meeting.
Health effects of trans fatty acids
The Joint WHO/FAO Expert Consultation on Diet, Nutrition 
and the Prevention of Chronic Disease (WHO, 2003; Nishida 
et al., 2004) confirmed that dietary TFAs have adverse effects 
on blood lipoprotein profiles and coronary heart disease 
(CHD) risk impacting individuals and populations. The 
adverse effects on CHD are mediated by increases in plasma 
concentrations of low-density lipoprotein cholesterol (LDL- 
C) and lipoprotein(a) (Lp(a)), and reductions in high-density 
lipoprotein cholesterol (HDL-C), promotion of inflamma­
tion and endothelial dysfunction, and possible effects on 
coagulation, insulin resistance and displacement of essential 
fatty acids from membranes, affecting prostanoid-related 
functions and possibly other key membrane-related func­
tions. The current body of evidence further indicates that 
TFA enhances multiple cardiovascular risk factors and 
increases CHD-related events.
As part of this WHO Scientific Update on TFA, the 
evidence for effects of TFA consumption on CHD was 
reviewed (Mozaffarian et al., 2009). Controlled trials and 
observational studies provide concordant evidence that 
consumption of TFA from partially hydrogenated oils 
adversely affects several cardiovascular risk factors and 
contributes significantly to an increased risk of CHD events. 
Despite the inherent differences in chemical structure, 
limited evidence indicates that industrial and ruminant 
TFAs may have similar effects on serum lipoproteins when 
ruminant TFA are consumed in sufficient quantities (much 
higher than seen with usual dietary intakes) in experimental 
studies. TFAs increase the ratio of serum levels of total/ 
HDL-C, the best single lipid predictor of CHD risk, and 
therefore intakes of TFA should be avoided. Although 
ruminant TFAs cannot be removed entirely from the diet, 
their intake is low enough in most populations that they 
do not constitute a significant risk factor for CHD. Because 
TFAs produced by partial hydrogenation are not normally 
present naturally in foods and have no known health 
benefits, the group considered them as industrial additives; 
as such, food services, restaurants, and food and cooking fat 
manufacturers should avoid their use as well (Mozaffarian 
etal., 2009).
As reviewed by L'Abbe et al. (2009), the experience from 
Denmark indicates that it is possible to largely eliminate 
industrial TFAs in foods, whereas experiences from Canada 
and New York City indicate that focused efforts can also 
bring about reductions. Experiences from Argentina and 
India also illustrate successes and serve to demonstrate the 
variety of approaches that have been or can be used to 
remove TFA. Attention should also be given to possible 
health effects of TFAs created during other industrial 
processes, such as light deodorization of marine oils and 
prolonged deep-frying. The removal of partially hydro­
genated vegetable oil (PHVO), a main source of TFAs in 
processed foods, would result in substantial health benefits, 
with the greatest advantage obtained when TFAs are replaced 
by oils rich in polyunsaturated fatty acids (PUFAs) and/or 
monounsaturated fatty acids (MUFAs) (Mozaffarian and 
Clarke, 2009). Significant benefits would be expected based 
on both effects on cardiovascular risk factors in controlled 
trials and observed relationships with clinical CHD events.
Industrial TFA consumption is believed to increase cardio­
vascular risk in multiple ways. The effects consistently 
observed in both randomized controlled trials and obser­
vational epidemiological studies include changes in lipo­
proteins, increased LDL-C and Lp(a), reduced HDL-C and 
an increased total/HDL-C ratio; proinflammatory effects 
and endothelial dysfunction, assessed by both circulating 
markers and functional measures. Each of these effects is 
most prominent when contrasted with the effect of 
czs-unsaturated fats (PUFA or MUFA) replacement; the adverse 
effects of TFA on the total/HDL-C ratio and endothelial 
dysfunction have also been documented relative to saturated 
fatty acid (SFA) replacement. Controlled trials and obser­
vational studies suggest that high intakes of TFAs may worsen 
insulin resistance, particularly among susceptible individuals 
such as those with visceral adiposity, preexisting insulin 
resistance or lower physical activity; further studies are needed 
to confirm possible effects on weight gain and on diabetes 
incidence in normal individuals (Mozaffarian et al., 2009). 
Together these findings suggest that, among dietary fats, TFA 
consumption induces characteristic cardiovascular and meta­
bolic effects (Mozaffarian and Willett, 2007), aggravating 
multiple related interlinked pathways that appear linked to 
the insulin resistance syndrome. Long-term effects of habitual 
TFA consumption on clinical outcomes have not been assessed 
under fully controlled dietary conditions in humans; ethical 
limitations make it unlikely that such trials could ever be 
performed.
The differential effects of specific TFAs based on carbon 
chain length or trans isomer bond(s) position are less well 
established. Too few studies have evaluated partially hydro­
genated fish oils to draw strong conclusions on the
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difference between 18-carbon as compared to 20- or 22- 
carbon isomers on CHD risk. Performing controlled trials 
comparing 18:2 against 18:3, TFA isomers are limited by the 
relatively lower concentrations of these isomers in partially 
hydrogenated oils. In observational studies utilizing biomar­
kers of TFA consumption, both 18:1 and 18:2 isomers appear 
to contribute to risk of CHD; conversely, most studies did not 
detect any effect of 16:1 TFA. The available data also suggest 
that trans-18:2 isomers may be more strongly associated with 
CHD risk than trans-18:l isomers, but the current evidence 
on this is limited and precludes definitive conclusions. This 
distinction has potential implications as some processes, 
such as light hydrogenation or deodorization, may create 
proportionally more 18:2 trans isomers and thus could have 
greater effects than would be expected based on content of 
total TFA alone (Mozaffarian et al., 2009).
Experimental studies of ruminant trans fats are limited by 
difficulty in distinguishing effects of changes in TFA from 
changes in other fats in ruminant products; the few small 
trials reported to date provide inconclusive evidence on 
whether the effects of ruminant TFA are different from 
industrial TFA. However, evidence from observational studies 
in which estimated TFA consumption from industrial and 
ruminant sources of TFA has been distinguished and from 
studies in which specific TFAs have been measured utilizing 
biomarkers generally do not support an adverse effect of 
ruminant TFA, in the low amounts usually consumed, on risk 
of CHD. Whether very high intakes of ruminant TFA could 
affect CHD risk is unresolved, but because consumption levels 
are low this does not appear to be critical in practice.
CHD effects of replacing PHVO with other fats/oils
A growing number of food manufacturers, restaurants and 
government agencies have implemented or are considering 
voluntary, labeling initiatives or regulatory efforts to reduce 
the content of industrial TFA in foods. On the basis of 
changes in blood lipids, for example, the ratio of total/ 
HDL-C in short-term randomized controlled trials and on 
associations of habitual TFA consumption with disease 
outcomes in prospective cohort studies, the estimated effects 
on CHD risk of replacing TFA with equivalent calories 
from carbohydrate or cis-unsaturated fats were previously 
estimated. However, in practice, TFAs in foods cannot be 
specifically fully replaced on a 1:1 basis by other nutrients. 
Rather, PHVO or other fats/oil sources that contain TFAs 
must be removed and replaced with alternative fats or oils. A 
variety of alternatives to PHVO include different combina­
tions of SFA, PUFA and MUFA, for example, vegetable oils, 
tropical oils, lard or butter (Mozaffarian and Clarke, 2009).
The predicted effects on CHD risk of replacing different 
PHVO formulations with alternative fats and oils were 
calculated (Mozaffarian and Clarke, 2009). To provide the 
more robust and reliable estimates of the importance of TFA 
for CHD risk, they performed two quantitative estimates: the 
first based on the effects of dietary fats (TFA, SFA, MUFA and 
PUFA) on blood lipids, lipoproteins and C-reactive protein 
(CRP) obtained from randomized controlled trials, and the 
second based on the relationship of habitual consumption of 
dietary fats with CHD events based on data from prospective 
observational studies.
To establish the quantitative effects of TFA consumption, 
as a replacement for other fats, on blood lipids, apolipopro­
teins and Lp(a), Mozaffarian and Clarke (2009) performed a 
meta-analysis of 13 randomized controlled dietary trials. 
This demonstrated clear effects of TFA, in comparison with 
SFA, MUFA or PUFA, on blood lipid concentrations, ApoB, 
ApoA-I and Lp(a). Notable effects of TFA included an increase 
in the total/HDL-C ratio and ApoB levels, particularly versus 
MUFA or PUFA but also versus SFA; lower HDL-C and ApoA-I 
and an increase in Lp(a). The effects on ApoB and ApoA-I 
were only partly attenuated (~50%) after adjustment for 
changes in the total/HDL-C ratio, indicating that TFA 
consumption independently affects both blood lipid concen­
trations and apolipoprotein levels. A separate meta-analysis 
of prospective cohort studies evaluating habitual TFA 
consumption and CHD events demonstrated that a 2% 
higher energy intake from TFA, as an isocaloric replacement 
for carbohydrate, was associated with 24% higher CHD risk 
(Mozaffarian and Clarke, 2009).
Results of calculations predicting changes in CHD risk 
indicated that replacement of PHVO (having 20, 35 or 45% 
TFA) providing 7.5% total energy with any of the alternative 
fats/oils would lower CHD risk, though the magnitude of 
the predicted benefits varied. For a 20% TFA PHVO, 
replacement with butter would have minimal effects on 
CHD risk, whereas replacement with vegetable oils would 
lower risk by ~ 10%. For PHVO with 35 or 45% TFA, any of 
the alternative fats/oil, including butter, lard, palm oil or 
vegetable oils, would lower risk by 12-20%, with larger 
benefits coming from vegetable oils compared with 
animal fats.
A comparison of these results—the estimates based on 
documented effects on cardiovascular risk factors in 
controlled trials versus observed associations between diet­
ary intakes and CHD events in cohort studies—serve to 
derive important conclusions relevant to quantitating the 
risk from TFA consumption (Mozaffarian and Clarke, 2009). 
First, for the replacement of PHVO with butter, lard or palm 
oil, the predicted effects based on risk factor changes 
obtained from short-term randomized trials were qualita­
tively and quantitatively similar to those derived from 
observed associations obtained from observational cohort 
studies of long-term differences in diet. The effects of TFA on 
risk factor levels consistently accounted for most (65-80%) 
of the differences in CHD risk reduction predicted by the 
observational studies, suggesting that most of the observed 
effects may be explained by effects on total/HDL-C ratio, 
ApoB, ApoA-I, Lp(a) and CRP.
Conversely, for the replacement of PHVO with different 
vegetable oils, the predicted effects on CHD based on risk
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factor changes from trial data accounted for only ~ 50% of 
the estimated effects derived from observed associations in 
cohort studies. This could be due to either underestimation 
of benefits based on risk factor changes in trials or over- 
estimation of benefits based on CHD incidence from cohort 
studies. Because the estimates of CHD benefits of vegetable 
oils calculated only from changes in selected risk factors 
(total/HDL-C ratio, ApoB, ApoA-I, Lp(a) and CRP) may not 
account for other benefits (for example, on insulin sensitiv­
ity or endothelial function), the magnitude of benefits 
calculated from the cohort studies may be closer to the true 
effects (Mozaffarian and Clarke, 2009). The analysis identi­
fied several strengths and potential limitations of the 
approach taken in these estimations (for additional details 
see Mozaffarian and Clarke, 2009). However, these analyses 
of data suggest that when removing PHVO from foods, 
manufacturers and restaurants should take advantage of the 
expense and effort of food reformulation to maximize the 
overall healthiness of the foods by using cis-unsaturated fats 
for replacement.
The discussion by the experts on the merits and limita­
tions of the analysis presented by Mozaffarian and Clarke 
(2009) centered on its usefulness as a risk assessment and 
management tool. The group considered that the suggested 
approach was extremely useful provided there was informa­
tion on the energy from industrial TFA being consumed by a 
given individual or population and on the proportion of TFA 
in the PHVO being consumed. The overall approach is 
clearly useful to assess risk management options based on 
the prediction of potential effectiveness of the PHVO 
replacement by the specific oil/fat sources based on the 
health benefit to be derived. The absolute effects on risk will 
depend on the contribution of PHVO-derived energy being 
replaced. In addition, as the average TFA content of PHVO 
changes, so will the relative benefits in terms of the various 
replacement fat or oils. This is of relevance in the choice of 
alternative fats and oils used to replace PHVO; for example, 
the replacement of PHVO with butter might be beneficial for 
PHVO with higher content (35-45%) of TFA but neutral for 
PHVO with lower content (< 20%) of TFA. Unfortunately, for 
most countries the quality of data on TFA content of PHVO 
and the %E from industrially derived TFA consumed is 
insufficient if available at all. Nevertheless, these data 
indicate, based on the currently available evidence, the best 
estimates of effects of replacing PHVO with different fats or 
oils, with direct implications for product reformulation by 
manufacturers and restaurants.
Another critical element of the Mozaffarian and Clarke's 
(2009) proposal was selection of indicators to define CHD risk 
reduction because the choice of lipoprotein outcome as 
affected by the replacement fat is highly relevant to the final 
conclusions. Total/HDL-C ratio and the ApoB/ApoA-I, rather 
than solely LDL-C, were chosen as two of the criteria by which 
the predicted risk can be estimated. On the other hand, if the 
analysis were to be based exclusively on the changes in LDL-C 
as the only factor to define risk reduction, the effect of 
replacement of PHVO with animal fats and tropical oils would 
appear considerably less beneficial, particularly if the PHVO 
has the lower TFA relative content (tropical oils and animal 
fats rich in lauric and palmitic acid raise both LDL-C and HDL-C 
in comparison to TFAs that raise LDL but lower HDL). Some of 
the experts believed that the latter approach would be supported 
by the evidence from drug trials of statins in which the absolute 
reduction in CHD risk is largely determined by lowering of 
LDL-C; however, others believed that such extrapolation of the 
results of controlled trials of statin therapy to potential effects of 
dietary interventions could not be justified. However, the group 
in examining both alternatives agreed with the proposed model 
based on both HDL and LDL effects highlighting the need for 
close monitoring of both the fatty acid composition of the oils 
sources to be used in replacement but also the biological impact 
in terms of lipoprotein levels and actual risk reduction within 
the specific populations being intervened.
The challenge to agriculturists and food producers by TFA 
replacement is to examine the issue in a comprehensive way 
starting from the breeding of oil seeds, through to the 
production of edible fats and oils, food processing and final 
consumption, considering the impact of the changes on human 
health, on the environment and on the availability of 
replacement fats and oils in a particular region. The ultimate 
goal of TFA elimination is to maximize the benefits, minimizing 
risk for human health and the environment in a cost-effective 
way. The actual choices of fats and oils used in many countries 
will be restricted by availability, actual costs of the replacement 
alternatives and their capacity to innovate.
Feasibility of recommending replacement fats
The 2002 Joint WHO/FAO Expert Consultation on Diet, 
Nutrition, and the Prevention of Chronic Diseases recom­
mended that mean population intake of TFA, for example, 
hydrogenated oils and fats, should be less than 1% of daily 
energy intake. This figures correspond to at most 2% of total 
fat (WHO, 2003). Although this recommendation was based 
on an extensive body of epidemiological and experimental 
evidence concerning the health effects of TFAs, the evidence 
upon which to judge the feasibility of recommending 
particular replacement or alternative fats is not as accessible 
or of similar quality (Skeaff, 2009). The use of PHVO 
containing TFA is widespread in the global food supply as 
ingredients in manufactured foods, in foods prepared in the 
food service industry and as cooking fats in the home in 
lower income countries. Although there is limited informa­
tion about the distribution of TFA intakes in most countries, 
it is likely that many subgroups within the population, 
particularly those who use PHVO for cooking or consume a 
high proportion of industrially processed foods or restaurant 
foods, would have mean TFA intakes considerably higher 
than the population mean. Thus, evaluation of mean 
population intakes is insufficient; the distribution of those 
at higher risk should also be evaluated.
European Journal of Clinical Nutrition
S72
WHO Scientific Update on TFAs
R Uauyeta/
Present knowledge on TFA intakes in most countries is not 
robust because it is often obtained from pragmatic dietary 
assessment surveys that do not rely on nutrient composition 
databases with complete TFA data. The transition phase in 
implementing governmental and/or industry-led initiatives 
to reduce TFA in the diet offers an excellent opportunity to 
develop or to strengthen existing nutrient and fatty acid 
food composition databases. The monitoring of TFA reduc­
tion or elimination policies should consist of systematic 
sampling and analysis of foods likely to contain PHVO and 
analysis of the saturated fat content of reformulated foods 
once TFAs have been removed. Furthermore, biomarkers 
should be used to assess TFA exposures in representative 
samples of the population. Monitoring is not only for the 
purpose of assessing changes in TFA intakes but also to assess 
the fatty acids that replace them. The effort to monitor the 
impact of regulatory and nonregulatory initiatives on TFA 
intakes should be commensurate with the degree of effort 
their introduction has required (Skeaff, 2009).
Currently, there is an insufficient world supply of high 
czs-unsaturated, zero TFA replacement fats and oils to meet 
the demand if all PHVO were to be removed from the global 
food supply over a short period of time. Substitute vegetable 
oils with zero or low TFA and high czs-unsaturated fatty acid 
can replace PHVO and maintain food product quality. There 
is a clear need to alert oil seed producers and agriculturists 
that there will likely be a need for an increased supply of 
substitute oils and that this represents an opportunity to 
expand or develop new oil seed varieties. International 
efforts to reduce the use of PHVO by the agriculture and food 
industry will need to be coordinated with supplies of 
appropriate alternative oils to avoid a decrease in TFA intake 
accompanied by a larger increase in SFAs, which would 
reduce the potential health gain derived from the reformu­
lation of manufactured foods containing TFA.
The introduction of regulations to remove TFA from the 
food supply will require coordination with the food industry 
to increase the availability of cost-effective zero-TFA fats or oils 
that are higher in czs-unsaturated fatty acids and lower in SFAs 
(Skeaff, 2009). Considering all upfront costs are in product 
reformulation, the food industry should consider all elements 
of fat content, not just TFA, to create an overall healthier 
product. Regulatory measures to reduce TFA in the food supply 
should ideally be accompanied by efforts to monitor intake of 
TFA as well as intakes of other fatty acids likely to be used as 
substitutes. Removing industrially produced TFA requires the 
replacement of PHVO with alternative fats, preferably vege­
table oils high in czs-unsaturated fats rather than with fats and 
oils that are high in saturated fat. However, in the case of 
PHVO with very high TFA content, even replacement with 
saturated fat oils may convey some benefit. It is widely held 
that the easiest substitutions are to use tropical oils such as 
palm, palm kernel or coconut oils. Supply of these oils is 
abundant, the price is low, the food industry has long used 
them and their physical and sensory properties produce foods 
with favorable characteristics. However, replacing TFAs with 
vegetable oils high in PUFA and MUFA is the preferred option 
for health benefits. As TFAs are industrially made and not 
intrinsic to the food supply, there is no harm in removing 
them from the food supply, that is, eliminating use of 
TFA-containing PHVO should be considered as hazard 
removal, in line with risk management models used to address 
many other food safety issues.
Approaches to removing trans fatty acids from 
the food supply
In assessing the approaches to reduce or remove TFA from 
the food supply in industrialized and developing countries, 
the experts considered a number of successful public health 
initiatives adopted by government agencies and public 
health organizations in some cases with the collaboration 
of the food industry. The examples of past and current 
initiatives reviewed were from Denmark, Canada, United 
States (New York City), Argentina and India. These include 
nutrition recommendations about TFAs and the selection of 
healthy fats, awareness programs through nutrition and 
health claims on the adverse effects of TFAs, voluntary or 
mandatory labeling of the trans content of foods, voluntary 
or legislated programs to encourage industry to reformulate 
food products in an effort to remove TFA, promoting the 
reduction of TFAs through health and agricultural policies 
that also support the production of healthy alternatives, and 
mandatory regulation of food standards to remove or reduce 
TFA content (L'Abbé et al., 2009).
The public health initiatives implemented in Denmark to 
eliminate the consumption of TFA appeared to provide a 
model for other countries worldwide, as it involved a 
multisectoral approach supported by widespread media and 
political involvement. Their efforts involved a solid science 
base of population intake patterns, risk assessment of 
exposure to TFA and economic considerations, which lead 
to risk management policies that received wide-based 
political support from both the community and the govern­
ment. The results were closely monitored and disseminated 
widely both in the scientific literature and in the lay press. 
The driving force in the process to virtually eliminate the 
consumption of industrially produced TFA in Danish foods 
was the Danish Nutrition Council. In the neighboring 
Nordic countries a different approach was chosen. Self­
regulation by industry has resulted in markedly reduced 
intakes of TFA from PHVO. Total TFA intakes have been 
reduced to O.S-O.8% of energy intake in Finland and Norway 
despite not having taken up legislation similar to that of 
Denmark, as ongoing reduction in the TFA content of the 
frying oil used by European fast food chains may have been 
triggered by the Danish example.
Since the late 1970s, Canadian scientists have raised 
concerns about the detrimental effects of rising TFA levels 
in the diet, first focusing on margarines and subsequently 
these warnings led to national recommendations. This focus
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on TFA led to the development of a number of fat spreads 
with low TFA specifically targeted to health-conscious 
consumers. However, the use of PHVOs continued to 
increase in other categories of processed foods. The 
estimated TFA intakes placed Canadians among those 
populations with the highest exposure to TFAs in the world 
during the mid-1990s. In recognition of these concerns and 
various local and international initiatives, Canada became 
the first country to require that TFA levels be included in the 
mandatory nutrition label on prepackaged foods. Currently 
available evidence from Canada demonstrates that the TFA 
reduction strategy is having the desired effect.
Further actions that affect food services and restaurants 
have been taken by Canada at the municipal and provincial 
level as well as by the United States at the state and city level. 
These include a variety of measures to reduce and/or to 
eliminate industrially derived TFAs in foods, for example, 
bans on foods containing high levels of TFA from school 
cafeterias, hospitals, day-care centers and other institutions 
under local jurisdiction. The example of New York City is 
one of best known because it has been widely disseminated 
by mass communication media (including TV and news­
papers). As one of the first cities to limit trans fats on a wide 
scale, the New York City Board of Health on 5 December 
2006 approved an amendment to their Health Code to phase 
out artificial trans fat in all New York City restaurants and 
other food service establishments. This was planned as a two- 
stage process; in the first stage, by 1 July 2007, all restaurants 
had to ensure that all oils, shortening and margarines 
containing industrially derived trans fat used for frying or 
for spreads had less than 0.5 g of trans fat per serving; by 
1 July 2008, all foods sold in restaurants would be required to 
have less than 0.5 g of trans fat per serving if they contain 
any industrially derived trans fat. The New York City 
Department of Health and Mental Hygiene has prepared a 
number of information materials to assist restaurants in 
reformulating products and to comply with the new 
regulations. Although the amendments to phase out trans 
fats from restaurants and other food service establishments 
in New York City are still underway and an evaluation of the 
results and impact of the New York City amendments has yet 
to be published, New York City Department of Health staff 
plan to publish this in the near future (L'Abbé et al., 2009).
In 1990, the Program for the Prevention of Infarcts in 
Argentina (PROPIA) was created, supported by La Plata 
National University, the Buenos Aires Scientific Investiga­
tions Commission and the Buenos Aires Health Ministry. 
Results from baseline evaluations conducted in Balcarce city 
showed that almost all foods contained high levels of TFAs 
and <o-3 fatty acids were practically absent in the local diet. 
This investigation was the starting point for the planning of 
intervention strategies necessary to modify the situation 
observed in Balcarce city. Successful collaboration with the 
suppliers of fats and oils and the food industry from 2001 
served to secure a stable supply of replacement fats and oils; 
product reformulation was actively encouraged by providing 
a tax bonus to those companies that met the suggested WHO 
limit of less than 1% of energy from TFA in specific food 
products. These actions served to facilitate government 
efforts in establishing public policies to promote healthier 
choices in diet and physical activity in line with the WHO 
Global Strategy to prevent nutrition related chronic disease. 
The systematic mass media dissemination of the trans fat 
reduction program served as a strong incentive because it 
created a demand for trans-iree products that translated into 
a commercial advantage. In addition, the Mercosur (the 
South American Common Market integrated by Argentina, 
Brazil, Paraguay and Uruguay) agreed in July 2007 on a 
regulation that all foods must include information on its 
trans content. As a result of this successful experience, in 
2005 the regional UNU network of Latin American institu­
tions part of the United Nations University Food and 
Nutrition Program asked PROPIA to lead an applied research 
program to evaluate the health impact of interventions 
addressed at improving the quality of the fat supply carried 
out in the Latin America (Uruguay, Chile, Mexico and several 
Central American countries).
Today, India faces the double burden of malnutrition due 
to chronic energy deficiency (associated with low intakes of 
nutrients including n-3 PUFAs) and also rising prevalence of 
diet-related chronic diseases. A wide range of oilseeds occupy 
a prominent place in the national food economy of India, 
second only to cereals. Vanaspati, a PH VO that contains TFA, 
is widely used in the preparation of commercially fried, 
processed, ready-to-eat and street foods, and for the 
preparation of Indian snacks, sweets and savory items, 
frozen foods, packaged and premixed foods. The high intake 
of TFA may be part of several changes in dietary and other 
lifestyle patterns contributing to the present day high 
prevalence of diet-related chronic diseases in India. Because 
a large proportion of the Indian population is predisposed to 
insulin resistance and there is a high prevalence of diabetes 
and CHD, the reduction of TFA from partially hydrogenated 
oils and foods consumed in India needs to be actively 
pursued on grounds of the projected health benefits.
The analysis of the case of India suggests some recom­
mendations can be of relevance to other developing 
countries facing a similar situation. Considerations to take 
into account in policies to address the reduction and/or 
elimination of industrially derived TFA, including the food 
processing industry, should use blends of natural vegetable 
oils that furnish higher stability to products wherever 
feasible, especially indigenous oils with potentially addi­
tional health benefits; the government should consider 
specifying achievable lower limits for TFA and SFA content 
in vegetable oil products, refined oils and processed foods; 
labels on processed foods should provide the content of TFA 
and SFA separately and state the optimal recommended 
ranges based on local conditions and options within the 
socioeconomic reality of the country; restaurants should 
disclose the use of 'partially hydrogenated oils' in served 
preparations; consumer awareness should be heighten
European Journal of Clinical Nutrition
S74
WHO Scientific Update on TFAs
R Uauyeta/
through food-based dietary guidelines regarding the 
negative health impact of TFA and the need to reduce TFA 
content of foods; and the food industry should replace 
hydrogenation technology with newer technologies that 
produce zero trans fats with desired functionality for various 
food applications.
Overall a multisectoral and proactive approach is required 
to successfully reduce or remove industrially produced 
TFAs from the food supply. In the example of the edible 
oil and food industries support, investment and incentives 
to develop, establish and operate new technologies will be 
needed.
Conclusions
The current growing body of evidence from controlled trials 
and observational studies indicates that TFA consumption 
from partially hydrogenated oils adversely affects multiple 
cardiovascular risk factors and contributes significantly to 
increased risk of CHD events. Although ruminant TFAs 
cannot be removed entirely from the diet, their intake is low 
in most populations and to date there is no conclusive 
evidence supporting an association with CHD risks in the 
amounts usually consumed. In contrast, TFA produced by 
partial hydrogenation of fats and oils should be considered 
industrial food additives having no demonstrable health 
benefits and clear risks to human health. The WHO Scientific 
Update on TFA concludes that restaurants and food manu­
facturers should avoid using industrially derived TFA in food 
products and that governments should take steps to support 
alternative fats or oils for TFA replacement The evidence on 
the effects of TFA and disease outcomes strongly supports the 
need to remove PHVO from the human food supply. The 
result would be a substantial health gain for the population 
at large, with greatest health benefits obtained when 
replacement oils are rich in n-3 and n-6 PUFA and in 
MUFA. Additionally, controlled studies and observational 
studies suggest that TFA may worsen insulin resistance, 
particularly among predisposed individuals with risk factors, 
for example, preexisting insulin resistance, visceral adiposity 
or lower physical activity. Further studies are needed to 
confirm the apparent effects of TFA on weight gain and 
diabetes incidence in humans.
Findings indicate that the replacement of TFAs in PHVO 
with alternative fats and oils would lower CHD risk through 
mechanisms beyond changes in blood lipid levels, thus 
explaining in large part the difference derived from estimates 
based on controlled dietary interventions focusing mainly 
on serum cholesterol fractions versus prospective cohort 
studies having CHD events as the outcome. Health benefits 
are projected to be greatest for replacement of PHVO with 
vegetable oils, but even replacement with tropical oils or 
animal fats would result in benefits, particularly for PHVO 
having higher (35-45%) levels of TFA as consumed in some 
developing countries. Thus, the choice of replacement fat/oil 
for PHVO needs to consider the effect of the replacement oil 
as well as the level of risk associated with the specific TFA 
containing sources to be replaced. It is also important to 
consider environmental sustainability in choosing appro­
priate replacement fats and oils.
Manufacturers, restaurants and food services should take 
advantage of making the most of the effort required for food 
product/preparation reformulations to not only reduce the 
TFA content but also maximize the overall healthiness of 
the foods destined for human consumption by increasing 
the content of czs-unsaturated fats. Reformulation should 
consider in the upfront potential cost-benefit analysis, not 
only TFA removal but also the favorable health conse­
quences of using the most healthful fats and oils for TFA 
replacement during product reformulation.
The evidence to assess a specific source of fats/oils as a 
replacement or alternative to TFAs reflects the complexity 
of the corresponding scientific evidence. The use of PHVO- 
containing TFA is widespread in the global food supply as a 
basic ingredient of manufactured foods and food prepara­
tions used and sold by the food service industry. Although 
there is limited information on the distribution of TFA 
intakes in most countries, it is likely that many subgroups 
within the population, particularly those who use PHVO for 
cooking in the home (common in developing countries) or 
consume a high proportion of bakery foods or fast-service 
restaurant foods, have mean TFA intakes considerably higher 
than the population mean. Removing industrially produced 
TFA requires the replacement of PHVO with alternative fats, 
preferably vegetable oils high in czs-unsaturated fats. How­
ever, in the case of PHVO with very high TFA content, 
replacement even with fats and oils high in SFAs may convey 
some, albeit smaller, benefit. The introduction of regulations 
to remove TFA from the human food supply will require 
coordination with the food industry and agricultural and 
food production sectors to increase the supply and to reduce 
the cost of their substitution by zero TFA, czs-unsaturated fat 
and oil sources that are also low in SFAs; thus, increasing cost 
effectiveness of the proposed intervention.
The experts acknowledged the need to review the current 
recommendation that the mean population intake of TFA, 
that is, partially hydrogenated oils and fats, should be less 
than 1% of daily energy intake. There is sufficient epide­
miological and experimental evidence to support revising 
this recommendation so that it encompasses the great 
majority of the population, and not just the population 
mean, to protect large subgroups from having high intakes. 
This could be accomplished, and has been in some countries 
and cities, by the virtual elimination of PHVO in the human 
food supply. The outcomes of this Scientific Update provide 
the evidence and scientific bases to promote discussions 
between the international scientific community related to 
nutrition and health as well as to agriculture and food 
production, relevant health professionals, national and 
international food regulatory agencies, civil society and the 
private sector to achieve this goal.
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